COVID-19 Challenge Study (COV-CHIM 01)

What is the purpose of this study and why participate?

SARS-CoV-2 is the virus responsible for COVID-19 disease. Recent roll out of licensed vaccines is a positive step towards fighting COVID-19. However, we don’t know how long protection after COVID-19 infection and/ or vaccination lasts and why some people can get infected a second time.

POInT

The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.